Conferences
Stay informed about upcoming pharma conferences, symposiums, and events. Discover opportunities to connect with industry experts, thought leaders, and researchers. Stay updated about the latest scientific advancements, networking opportunities, and educational programs in the pharmaceutical field.
Innate Pharma Showcases Breakthrough Tetra-Specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress
Source: Innate Pharma On June 10, 2023, Innate Pharma, a biopharmaceutical company, highlights the latest preclinical findings on IPH6501, a ...
Kura Oncology Unveils Promising Clinical Results of Ziftomenib, at the 2023 European Hematology Association (EHA) Congress
Source – Kura Oncology Kura Oncology presented updated clinical data for its menin inhibitor, ziftomenib, at the 2023 European Hematology ...
Danicopan Shows Promise as an Add-On to Ultomiris or Soliris, Enhancing Hemoglobin Levels and Disease Control in PNH Patients
Source – AstraZeneca Promising outcomes emerged from the pivotal Phase III ALPHA trial, revealing that danicopan, an investigational oral Factor ...
ASCO 2023: Unlocking the Potential of TGF-β Inhibition
ABSTRACT NUMBER: 6026 Recent studies have underscored the crucial role of the TGF-β signalling pathway in shaping the immune microenvironment ...
ASCO 2023: Empowering Responses in Follicular Lymphoma: Epcoritamab Combines with Rituximab and Lenalidomide to Unleash Promising Outcomes
ABSTRACT NUMBER: 7506 Epcoritamab, a novel bispecific antibody targeting CD3 and CD20, has demonstrated potent T-cell-mediated cytotoxic activity against CD20-positive ...
ASCO 2023: Unleashing Precision: AFNT-211 Targets KRAS G12V Mutations in Solid Tumours with Potent Efficacy
ABSTRACT NUMBER: 2543 KRAS mutations are commonly found in various solid tumours and play a significant role in cancer development ...
ASCO 2023: Zanidatamab – A New Hope for HER2-Amplified Biliary Tract Cancers
ABSTRACT NUMBER – 4008 A subset of biliary tract cancer cases presents either with overexpression or amplification of the HER2 ...
ASCO 2023: Oncolytics Unleashes Revolutionary Results for Breast Cancer Immunotherapy
ABSTRACT NUMBER – 1012 Preclinical studies have demonstrated that the oncolytic reovirus Pelareorep can enhance the tumor microenvironment by promoting ...
ASCO 2023: Toripalimab Combination Therapy – A Breakthrough for TNBC
ABSTRACT NUMBER – LBA1013 Combining taxanes-based chemotherapy with checkpoint blockade yields diverse outcomes in the first-line metastatic triple-negative breast cancer ...
ASCO 2023: How NALIRIFOX Can Extend the Lives of Patients with Metastatic Pancreatic Cancer
ABSTRACT NUMBER – 4006 The combination of liposomal irinotecan with 5-fluorouracil/leucovorin (5-FU/LV) has already received approval for treating metastatic pancreatic ...
ASCO 2023: Elicio Therapeutics Unveils Promising Interim Results from AMPLIFY-201 Phase I Trial of Cutting-Edge Cancer Immunotherapy
ABSTRACT NUMBER – 2528 ELI-002 represents a new therapeutic vaccine called AMP that specifically targets KRAS-driven cancers. KRAS mutations are ...
ASCO 2023: New SERM Drug Offers Hope for Metastatic Breast Cancer Patients
ABSTRACT NUMBER – 1057 We have received a thorough explanation of SERDs. However, a selective estrogen receptor modulator (SERM) is ...
Sotorasib vs Docetaxel in KRAS G12C-Mutated NSCLC: ASCO 2023 Highlights
ABSTRACT NUMBER – LBA9016 Amgen has made a courageous endeavor in cancer research over the last four decades by creating ...
ASCO 2023: ELAHERE – A New Hope for Platinum-Resistant Ovarian Cancer Patients
ABSTRACT NUMBER – LBA5507 The MIRASOL trial, presented at ASCO on June 4, demonstrated a significant improvement in the primary ...
ASCO 2023: How Linvoseltamab Can Treat Pretreated Myeloma Patients
ABSTRACT NUMBER – 8006 Linvoseltamab, an investigational bispecific antibody known as BCMAxCD3, shows promising potential in connecting B-cell maturation antigen ...
ASCO 2023: Patients with HER2-Positive MCRC Benefit from Lower Dose of Trastuzumab Deruxtecan
ABSTRACT NUMBER – 3501 The Phase II DESTINY-CRC02 study, presented at the 2023 ASCO Annual Meeting, reported that administering ENHERTU ...
ASCO 2023: Promising Results from Sleeping Beauty TCR-T Cells
ABSTRACT NUMBER – 2547 Alaunos’ Clinical TCR Library focuses on targeting the most common mutations found in KRAS, TP53, and ...
ASCO 2023:Kelun Pharma’s SKB264 shows early signs of potential in NSCLC patients
ABSTRACT NUMBER – 9114 SKB264 is an innovative anti-TROP2 ADC that specifically targets a poor prognosis marker found in 70% ...
EpicentRx Provides Latest Updates on Oncology Clinical Development Programs at 2023 ASCO Annual Meeting
During the 2023 American Society of Clinical Oncology (ASCO) meeting, EpicentRx, Inc., a clinical-stage biopharmaceutical company, provided updates on the ...
ASCO 2023: BREYANZI Shines as First CAR T Therapy with Deep and Lasting Impact in Chronic Lymphocytic Leukemia
The initial findings from the important TRANSCEND CLL 004 study, which is evaluating the use of BREYANZI (lisocabtagene maraleucel) in ...
